Because of a lapse in government funding, the information on this website may not be up to date transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at USA.gov.

NCI Drug Dictionary

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

Browse:
bevacizumab
Patient Information
A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels. Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:anti-VEGF humanized monoclonal antibody
anti-VEGF monoclonal antibody
anti-VEGF rhuMAb
bevacizumab biosimilar BEVZ92
bevacizumab biosimilar BI 695502
bevacizumab biosimilar CBT 124
bevacizumab biosimilar FKB238
bevacizumab biosimilar PF-06439535
immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain anti-human vascular endothelial growth factor), disulfide with human-mouse monoclonal rhuMab-VEGF light chain, dimer
recombinant humanized anti-VEGF monoclonal antibody
rhuMAb VEGF
US brand name:Avastin
Mvasi
Abbreviation:rhuMAb VEGF
rhuMab-VEGF